AbbVie

AbbVie's blockbuster eye drug Restasis under threat as FDA approves Viatris' copycat
AbbVie's blockbuster eye drug Restasis under threat as FDA approves Viatris' copycat
Fierce Pharma
AbbVie
earnings
Restasis
FDA
generics
Flag link:
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
AbbVie's Gonzalez: Skyrizi and Rinvoq to become Humira 2.0 — while adding an indication for atopic dermatitis
Endpoints
AbbVie
earnings
Rick Gonzalez
Skyrizi
Rinvoq
Flag link:
AbbVie notches reprieve in antitrust case involving blood pressure med snagged in $63B Allergan megamerger
AbbVie notches reprieve in antitrust case involving blood pressure med snagged in $63B Allergan megamerger
Fierce Pharma
AbbVie
antitrust
Bystolic
generics
Allergan
Flag link:
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
Yahoo/Zacks.com
AbbVie
Skyrizi
FDA
psoriatic arthritis
Flag link:
What This FDA News Could Mean for AbbVie's Stock
What This FDA News Could Mean for AbbVie's Stock
Motley Fool
AbbVie
Rinvoq
FDA
Flag link:
3 Clinical Trials to Watch in the First Half of 2022
3 Clinical Trials to Watch in the First Half of 2022
Motley Fool
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Roche
Alzheimer's disease
gantenerumab
AbbVie
cystic fibrosis
Flag link:
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B
Fierce Pharma
AbbVie
Rinvoq
Skyrizi
JPMHC 2022
Flag link:
AbbVie seeks approval for upadacitinib to treat nr-axSpA
AbbVie seeks approval for upadacitinib to treat nr-axSpA
Pharmaceutical Business Review
AbbVie
FDA
EMA
upadacatinib
nr-axSpA
non-radiographic axial spondyloarthritis
Flag link:
FDA grants breakthrough designation to AbbVie’s Teliso-V for NSCLC treatment
FDA grants breakthrough designation to AbbVie’s Teliso-V for NSCLC treatment
Pharmaceutical Business Review
FDA
AbbVie
Teliso-V
telisotuzumab vedotin
non-small cell lung cancer
Flag link:
10 clinical trials to watch in the first half of 2022
10 clinical trials to watch in the first half of 2022
BioPharma Dive
clinical trials
Pfizer
Arena Pharmaceuticals
etrasimod
Sanofi
GSK
vaccines
COVID-19
Roche
gantenerumab
AbbVie
Gilead Sciences
Trodelvy
Karuna Therapeutics
KarXT
Intercept Pharma
obeticholic acid
Allogene
ALLO-501a
Flag link:
Could This FDA Approval Create a Blockbuster Drug for AbbVie?
Could This FDA Approval Create a Blockbuster Drug for AbbVie?
Motley Fool
AbbVie
Rinvoq
FDA
psoriatic arthritis
Flag link:
Teva suffers trial loss in New York's landmark opioid case
Teva suffers trial loss in New York's landmark opioid case
Fierce Pharma
Teva Pharmaceutical
AbbVie
JNJ
New York
legal
opioids
opioid crisis
Flag link:
What AbbVie's Recent Drug News Means for Shareholders
What AbbVie's Recent Drug News Means for Shareholders
Motley Fool
AbbVie
Skyrizi
Crohn’s disease
Europe
Flag link:
What to Make of the FDA's Latest Warning to AbbVie and Pfizer
What to Make of the FDA's Latest Warning to AbbVie and Pfizer
Motley Fool
FDA
AbbVie
Pfizer
Rinvoq
Xeljanz
JAK inhibitors
Flag link:
Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial
Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial
Endpoints
Idera Pharmaceuticals
AbbVie
melanoma
clinical trials
tilsotolimod
Flag link:
Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change
Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change
Endpoints
Pfizer
AbbVie
Xeljanz
Rinvoq
FDA
JAK inhibitors
Flag link:
AbbVie prices first presbyopia drug Vuity at $80 per month
AbbVie prices first presbyopia drug Vuity at $80 per month
Pharmaforum
AbbVie
Vuity
presbyopia
Flag link:
AbbVie settles New York opioid case as trial winds down
AbbVie settles New York opioid case as trial winds down
Reuters
AbbVie
opioids
opioid addiction
New York
legal
Flag link:
Former Scripps and Humira Leader Richard Lerner Passes Away
Former Scripps and Humira Leader Richard Lerner Passes Away
BioSpace
Richard Lerner
Scripps Research Institute
AbbVie
Humira
Flag link:
Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut
Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut
Fierce Pharma
Alvotech
SPACs
AbbVie
Humira
Flag link:

Pages